A Phase I, multicenter, Open-label, Dose-Escalation and Expansion Study to evaluate the safety and tolerability of Iodine 131 labeled acitretide injection which is CEA targeting monoclonal antibody in the treatment of advanced malignant solid tumors

Trial Profile

A Phase I, multicenter, Open-label, Dose-Escalation and Expansion Study to evaluate the safety and tolerability of Iodine 131 labeled acitretide injection which is CEA targeting monoclonal antibody in the treatment of advanced malignant solid tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Nov 2017

At a glance

  • Drugs Iodine-131-actuximab (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 28 Nov 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top